Related Experiment Video

Updated: Oct 26, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.0K

Evaluation and management of drug resistant epilepsy in children

Gogi Kumar1

  • 1Dayton Children Hospital, Wright State University Boonshoft School of Medicine, 1 Children's Plaza, Dayton Ohio 45404.

Current Problems in Pediatric and Adolescent Health Care
|July 26, 2021
PubMed

Insights

Drug-resistant epilepsy (DRE) affects about 30% of children with epilepsy, leading to significant health and life impacts. This condition signifies a failure to respond to standard anti-epileptic drugs, necessitating further research and treatment strategies.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Epilepsy is a common childhood neurological disorder.
  • While most children respond to anti-epileptic drugs (AEDs), around 30% develop drug-resistant epilepsy (DRE).
  • DRE is characterized by the failure of adequate trials of two appropriately chosen and used AEDs.

Purpose of the Study:

  • To highlight the prevalence and definition of DRE in pediatric populations.
  • To underscore the serious consequences associated with DRE, including mortality and cognitive impairment.
  • To emphasize the profound impact of DRE on the lives of affected children and their caregivers.

Main Methods:

  • Literature review on pediatric epilepsy and drug resistance.
  • Analysis of the definition and diagnostic criteria for DRE.
  • Synthesis of data on outcomes and quality of life in children with DRE.

Main Results:

  • Approximately 30% of children with epilepsy exhibit drug resistance.
  • DRE is defined by the inefficacy of multiple tolerated anti-epileptic drug treatments.
  • Children with DRE face increased mortality risks and poorer cognitive outcomes.

Conclusions:

  • Drug-resistant epilepsy presents a significant challenge in pediatric neurology.
  • Effective management strategies for DRE are crucial to mitigate adverse outcomes.
  • Further research is needed to improve treatment efficacy and quality of life for children with DRE.

More Related Videos

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

20.6K
Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note05:54

Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

17.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
47
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
480
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
547
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
607
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
373
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
45